1. Home
  2. RVSN vs IMRN Comparison

RVSN vs IMRN Comparison

Compare RVSN & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rail Vision Ltd.

RVSN

Rail Vision Ltd.

N/A

Current Price

$4.38

Market Cap

10.9M

Sector

N/A

ML Signal

N/A

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$1.07

Market Cap

9.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVSN
IMRN
Founded
2016
1994
Country
Israel
Australia
Employees
47
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9M
9.6M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
RVSN
IMRN
Price
$4.38
$1.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
28.6K
147.3K
Earning Date
03-31-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$860.32
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.68
52 Week High
$9.39
$2.38

Technical Indicators

Market Signals
Indicator
RVSN
IMRN
Relative Strength Index (RSI) 31.21 43.48
Support Level $4.20 $0.72
Resistance Level $5.21 $1.24
Average True Range (ATR) 0.33 0.16
MACD 0.07 -0.03
Stochastic Oscillator 24.75 1.72

Price Performance

Historical Comparison
RVSN
IMRN

About RVSN Rail Vision Ltd.

Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: